Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Early diagnosis and treatment of frontal fibrosing alopecia are crucial to prevent permanent hair loss.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Frunevetmab injections in cats can cause severe itching and skin lesions.

Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.